Fixed-Duration Triplet Therapy Demonstrates Efficacy for Patients with Relapsed/Refractory CLL
June 14, 2026
June 14, 2026
BOSTON, Massachusetts, June 14 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:
* * *
Fixed-Duration Triplet Therapy Demonstrates Efficacy for Patients with Relapsed/Refractory CLL
*
A Dana-Farber Cancer Institute investigator presented positive interim data from the BRUIN CLL-322 trial, the first randomized phase 3 data to be reported about a Bruton tyrosine kinase (BTK) inhibitor as part of a fixe . . .
* * *
Fixed-Duration Triplet Therapy Demonstrates Efficacy for Patients with Relapsed/Refractory CLL
*
A Dana-Farber Cancer Institute investigator presented positive interim data from the BRUIN CLL-322 trial, the first randomized phase 3 data to be reported about a Bruton tyrosine kinase (BTK) inhibitor as part of a fixe . . .